At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 841 enrolled
Drug / intervention
albiglutide +1 morebiological
Likely dose
liraglutide 0.6mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide in Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating albiglutide and liraglutide for Diabetes Mellitus, Type 2. Completed, enrolled 841 participants across 173 sites in 8 countries.
Detailed Summary
This open-label study examines the efficacy and safety of albiglutide as compared with liraglutide in subjects with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesAustralia, Israel, Peru, Philippines, South Korea, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedMay 2010
Primary CompletionSep 2011
TodayJul 2026
First PostedMay 24, 2010
Enrollment StartMay 1, 2010
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.1 years ago
Interventions
albiglutidebiological
albiglutide weekly subcutaneous injection
liraglutidedrug
liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.